NCT02252887View on ClinicalTrials.gov

Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

January 12, 2015

Primary Completion Date

July 24, 2025

Study Completion Date

July 24, 2025

Conditions
Metastatic HER2-Positive Breast Cancer
Interventions
DRUG

Gemcitabine

DRUG

Trastuzumab

DRUG

Pertuzumab

Trial Locations (5)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

06102

Hartford Healthcare Cancer Institute @ Hartford Hospital, Hartford

07920

Memorial Sloan Kettering at Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

Sponsors
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Hoffmann-La Roche

INDUSTRY

collaborator

Hartford HealthCare

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT02252887 - Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy | Biotech Hunter | Biotech Hunter